Multidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: A meta-analysis

Ma,Limin; Liu,Hongchao; Ruan,Linhai; Yang,Xuewen; Yang,Haiping; Feng,Yanming

doi:10.3892/br.2014.387

Multidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: A meta-analysis

Authors:
- Limin Ma
- Hongchao Liu
- Linhai Ruan
- Xuewen Yang
- Haiping Yang
- Yanming Feng
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China, Medical College, Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: November 14, 2014 https://doi.org/10.3892/br.2014.387
Pages: 83-87

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several studies have investigated the association between multidrug resistance gene (MDR1) C1236T polymorphism and leukemia risk, however, these published studies have yielded conflicting results. Thus, the present study carried out a meta‑analysis to provide a more precise estimate of the effect of this polymorphism on the susceptibility to leukemia. The published case‑control studies regarding the association between MDR1 C1236T polymorphism and leukemia risk were included following a computerized search of PubMed, Elsevier, The Cochrane Library, China National Knowledge Infrastructure and Wanfang Database. Either fixed‑ or random‑effects models were applied to calculate the combined odds ratios (ORs) and 95% confidence intervals (CIs) by RevMan 5.2 software. Seven studies, including 846 cases and 1,523 controls, were included in the present meta‑analysis. The results indicated that there was no significant association between the MDR1 C1236T polymorphism and leukemia risk in overall comparisons in all four genetic models (CT vs. CC: OR, 1.31, 95% CI, 0.89‑1.91, P=0.17; TT vs. CC: OR, 2.16, 95% CI, 0.99‑4.70, P=0.05; TT vs. CC+CT: OR, 1.72, 95% CI, 0.91‑3.25, P=0.09; and CT+TT vs. CC: OR, 1.57, 95% CI, 0.96‑2.56, P=0.07). In the subgroup analysis according to specific ethnicity, age and the type of leukemia, a significant association was found in adult leukemia (CT+TT vs. CC: OR, 2.77, 95% CI, 1.05‑7.31, P=0.04) and chronic myeloid leukemia (CT vs. CC: OR, 1.71, 95% CI, 1.05‑2.80, P=0.03). No significant publication bias was detected by funnel plot. Therefore, the meta‑analysis indicated that the MDR1 C1236T polymorphism may contribute to the susceptibility to adult leukemia and chronic myeloid leukemia. Furthe well-designed studies based on larger sample sizes are required to validate these findings.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Inaba H, Greaves M and Mullighan CG: Acute lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar
3	Greaves M: Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 6:193–203. 2006. View Article : Google Scholar : PubMed/NCBI
4	Sherborne AL, Hosking FJ, Prasad RB, et al: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 42:492–494. 2010. View Article : Google Scholar : PubMed/NCBI
5	Vijayakrishnan J and Houlston RS: Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica. 95:1405–1414. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, Chen J, Li J, et al: Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population. Gene. 524:203–207. 2013. View Article : Google Scholar : PubMed/NCBI
7	Speedy HE, Di Bernardo MC, Sava GP, et al: A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 46:56–60. 2014. View Article : Google Scholar : PubMed/NCBI
8	Schinkel AH: The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 8:161–170. 1997. View Article : Google Scholar : PubMed/NCBI
9	Lin JH and Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 42:59–98. 2003. View Article : Google Scholar : PubMed/NCBI
10	Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE and Altman RB: Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 21:152–161. 2011. View Article : Google Scholar : PubMed/NCBI
11	Breier A, Barancík M, Sulová Z and Uhrík B: P-glycoprotein - implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 5:457–468. 2005. View Article : Google Scholar : PubMed/NCBI
12	Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 97:3473–3478. 2000. View Article : Google Scholar
13	Kurata Y, Ieiri I, Kimura M, et al: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 72:209–219. 2002. View Article : Google Scholar : PubMed/NCBI
14	Lamba J, Strom S, Venkataramanan R, et al: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 79:325–338. 2006. View Article : Google Scholar : PubMed/NCBI
15	Jamroziak K, Balcerczak E, Smolewski P, et al: MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep. 58:720–728. 2006.PubMed/NCBI
16	Hattori H, Suminoe A, Wada M, et al: Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res. 31:1633–1640. 2007. View Article : Google Scholar
17	Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D and Rajappa S: Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev. 11:1063–1066. 2010.PubMed/NCBI
18	Marzolini C, Paus E, Buclin T and Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 75:13–33. 2004. View Article : Google Scholar : PubMed/NCBI
19	Robert J, Morvan VL, Smith D, Pourquier P and Bonnet J: Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 54:171–196. 2005. View Article : Google Scholar : PubMed/NCBI
20	Brambila-Tapia AJ: MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin. 65:445–454. 2013.PubMed/NCBI
21	Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C and Wiemels JL: MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev. 16:1172–1177. 2007. View Article : Google Scholar : PubMed/NCBI
22	Liu RR: The role of multidrug resistance gene 1 polymorphism to prognosis of adult acute lymphoblastic leukemia patients. Central South University. 5:1–48. 2008.(In Chinese).
23	Gréen H, Falk IJ, Lotfi K, et al: Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 12:111–118. 2012.PubMed/NCBI
24	Lü H, Du ZZ, Wang W, et al: Relationship between genetic polymorphism of multidrug resistance 1 gene and the risk of childhood acute lymphocytic leukemia. Zhonghua Er Ke Za Zhi. 50:692–696. 2012.(In Chinese).
25	Singh O, Chan JY, Lin K, Heng CC and Chowbay B: SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One. 7:e517712012. View Article : Google Scholar : PubMed/NCBI
26	Vivona D, Bueno CT, Lima LT, et al: ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 48:132–136. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhai X, Wang H, Zhu X, et al: Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci. 8:659–671. 2012. View Article : Google Scholar : PubMed/NCBI
28	Elghannam DM, Ibrahim L, Ebrahim MA, Azmy E and Hakem H: Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology. 19:123–128. 2014. View Article : Google Scholar : PubMed/NCBI
29	Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, et al: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetic. 13:741–757. 2003. View Article : Google Scholar
30	Semsei AF, Erdélyi DJ, Ungvári I, et al: Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res. 32:1214–1220. 2008. View Article : Google Scholar : PubMed/NCBI
31	Yin JY, Huang Q, Yang Y, Zhang JT, Zhong MZ, Zhou HH and Liu ZQ: Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics. 19:206–216. 2009. View Article : Google Scholar
32	Qian X, Cao S, Yang G, Dong J, Jin G, Shen Y and Hu Z: Variant genotypes of MDR1 C3435T increase the risk of leukemia: evidence from 10 case-control studies. Leuk Lymphoma. 53:1183–1187. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yan Y, Liang H, Xie L, et al: Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis. Tumour Biol. 35:2191–2197. 2014. View Article : Google Scholar : PubMed/NCBI